Description

LCKLSL hydrochloride is a N-terminal hexapeptide and a competitive annexin A2 (AnxA2) inhibitor. LCKLSL hydrochloride potently inhibits the binding of tissue plasminogen activator (tPA) to AnxA2. LCKLSL hydrochloride also inhibits the generation of plasmin and has anti-angiogenic roles[1].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)–Neuroscience-Neuromodulation–C30H58ClN7O8S—J Neurochem. 2022 Mar;160(6):662-674.|Biomed Pharmacother. 2023 Mar;159:114173.|Inflamm Res. 2022 Jul 28.-[1]Mallika Valapala, et al. A Competitive Hexapeptide Inhibitor of Annexin A2 Prevents Hypoxia-Induced Angiogenic Events. J Cell Sci. 2011 May 1;124(Pt 9):1453-64.—-712.34–99.76–CC(C)C[C@@H](C(O)=O)NC([C@H](CO)NC([C@H](CC(C)C)NC([C@H](CCCCN)NC([C@H](CS)NC([C@H](CC(C)C)N)=O)=O)=O)=O)=O.Cl–Cardiovascular Disease–DMSO : 25 mg/mL (ultrasonic)|H2O : 10 mg/mL (ultrasonic)–Others—-Others–Peptides